As the U.K.'s cost-effectiveness watchdog NICE issues a final blessing for Bayer and Johnson & Johnson's anticoagulant Xarelto--for preventing strokes in atrial fibrillation patients--the drug faces a grilling at an FDA advisory committee meeting. The panel is weighing evidence for a new, potentially lucrative use in patients with acute coronary syndrome. Release | Live Blog